JP Morgan Chase’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-229,456
| Closed | -$17.3M | – | 7155 |
|
|
2022
Q2 | $17.3M | Sell |
229,456
-154,970
| -40% | -$6.89M | ﹤0.01% | 1723 |
|
|
2022
Q1 | $10.3M | Buy |
384,426
+65,212
| +20% | +$2.19M | ﹤0.01% | 2337 |
|
|
2021
Q4 | $15.2M | Buy |
319,214
+52,083
| +19% | +$2.33M | ﹤0.01% | 2066 |
|
|
2021
Q3 | $17.7M | Sell |
267,131
-16,586
| -6% | -$1.18M | ﹤0.01% | 1869 |
|
|
2021
Q2 | $22.1M | Buy |
283,717
+252,994
| +823% | +$18.7M | ﹤0.01% | 1755 |
|
|
2021
Q1 | $2.91M | Sell |
30,723
-16,996
| -36% | -$2.02M | ﹤0.01% | 3421 |
|
|
2020
Q4 | $5.82M | Buy |
47,719
+16,318
| +52% | +$1.79M | ﹤0.01% | 2678 |
|
|
2020
Q3 | $2.78M | Buy |
31,401
+11,216
| +56% | +$781K | ﹤0.01% | 3009 |
|
|
2020
Q2 | $1.3M | Sell |
20,185
-12,933
| -39% | -$746K | ﹤0.01% | 3360 |
|
|
2020
Q1 | $1.48M | Buy |
33,118
+11,910
| +56% | +$633K | ﹤0.01% | 3162 |
|
|
2019
Q4 | $1.32M | Buy |
21,208
+19,031
| +874% | +$906K | ﹤0.01% | 3658 |
|
|
2019
Q3 | $82K | Buy |
2,177
+353
| +19% | +$15.4K | ﹤0.01% | 4975 |
|
|
2019
Q2 | $71K | Buy |
+1,824
| New | +$65.1K | ﹤0.01% | 5049 |
|
JP Morgan Chase's TPTX Position: Q3 2022 in Review
JP Morgan Chase sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 229,456 shares — an estimated $17.3M sold.
JP Morgan Chase first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $22.1M in Q2 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- JP Morgan Chase reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- JP Morgan Chase sold 229,456 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $17.3M.
- JP Morgan Chase first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- JP Morgan Chase's Turning Point Therapeutics, Inc. Common Stock position peaked at $22.1M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on JP Morgan Chase's 13F filing for Q3 2022, filed 14 Nov 2022.